Figure 3.

Effect of celecoxib, a COX-2 inhibitor, on the expression levels of β-catenin and downstream targets of β-catenin, MMP-2 and MMP-9, in A375 and Hs294t melanoma cells. A375 (A) and Hs294t (B) cells were treated with celecoxib (0, 5, 10, and 20 µM) for 24 h, then cells were harvested, cytoplasmic and nuclear fractions isolated and subjected to western blot analysis. Treatment of celecoxib inhibits the expression levels of β-catenin, MMP-2 and MMP-9 in both A375 and Hs294t melanoma cell lines in a dose-dependent manner.